HIV and the Liver

Sherlock's Diseases of the Liver and Biliary System, 12th Edition

Volumn , Issue , 2011, Pages 438-451

  Peters, Marion G ^a   Soriano, Vincent ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral therapy; Hepatitis B coinfection; Hepatitis C coinfection; Hepatitis D coinfection; Hepatitis vaccination in HIV; Hepatotoxicity; Non cirrhotic portal hypertension; Opportunistic infection

Indexed keywords

EID: 80855166273     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341294.ch22     Document Type: Chapter

References (84)

1. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodefi-ciency virus: the D: A: D study. Arch. Intern. Med. 2006; 166: 1632-1641.
2. Overton ET, Sungkanuparph S, Powderly WG et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin. Infect. Dis. 2005; 41: 1045-1048.
3. Collier AC, Corey L, Murphy VL et al. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann. Intern. Med. 1988; 109: 101-105.
4. Rivas P, Herrero MD, Puente S et al. Immunizations in HIV-infected adults. AIDS Rev. 2007; 9: 173-187.
5. Hofer M, Joller-Jemelka HI, Grob PJ et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Eur. J. Clin. Microbiol. Infect. Dis. 1998; 17: 6-13.
6. French AL, Lin MY, Evans CT et al. Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women. Clin. Infect. Dis. 2009; 49: 148-154.
7. Gandhi RT, Wurcel A, Lee H et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J. Infect. Dis. 2005; 191: 1435-1441.
8. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N. Engl. J. Med. 2007; 356: 1445-1454.
9. Hadler SC, Judson FN, O'Malley PM et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J. Infect. Dis. 1991; 163: 454-459.
10. Peters MG, Andersen J, Lynch P et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44: 1110-1116.
11. Thio CL, Seaberg EC, Skolasky R, Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
12. Hoffmann CJ, Seaberg EC, Young S et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23: 1881-1889.
13. Idoko J, Meloni S, Muazu M et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin. Infect. Dis. 2009; 49: 1268-1273.
14. Rockstroh JK, Bhagani S, Benhamou Y et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008; 9: 82-88.
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services, 2009.
16. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-1306.
17. McMahon MA, Jilek BL, Brennan TP et al. The HBV drug entecavir-effects on HIV-1 replication and resistance. N. Engl. J. Med. 2007; 356: 2614-2621.
18. Milazzo L, Caramma I, Lai A et al. Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. Antivir. Ther. 2009; 14: 869-872.
19. Crane M, Oliver B, Matthews G et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J. Infect. Dis. 2009; 199: 974-981.
20. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J. Gen. Virol. 2006; 87: 1439-1449.
21. Sulkowski MS, Mehta SH, Torbenson MS et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21: 2209-2216.
22. Benhamou Y, Bochet M, Di MV et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
23. Danta M, Brown D, Bhagani S et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983-991.
24. Sherman KE, Rouster SD, Chung RT et al. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin. Infect. Dis. 2002; 34: 831-837.
25. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456.
26. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-1089.
27. Martin-Carbonero L, Benhamou Y, Puoti M et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin. Infect. Dis. 2004; 38: 128-133.
28. Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
29. Soriano V, Labarga P, Ruiz-Sancho A et al. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS 2006; 20: 2225-2227.
30. Uberti-Foppa C, De Bona A, Morsica G et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 2003; 33: 146-152.
31. de Ledinghen V, Douvin C, Kettaneh A et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J. Acquir. Immune. Defic. Syndr. 2006; 41: 175-179.
32. Sterling RK, Contos MJ, Sanyal AJ et al. The clinical spectrum of hepatitis C virus in HIV coinfection. J. Acquir. Immune. Defic. Syndr. 2003; 32: 30-37.
33. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
34. Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 2004; 351: 451-459.
35. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. eginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 2004; 351: 438-450.
36. Torriani FJ, Ribeiro RM, Gilbert TL et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J. Infect. Dis. 2003; 188: 1498-1507.
37. Nunez M, Miralles C, Berdun MA et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res. Hum. Retroviruses 2007; 23: 972-982.
38. Alberti A, Clumeck N, Collins S et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J. Hepatol. 2005; 42: 615-624.
39. Martin-Carbonero L, Nunez M, Marino A et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008; 22: 15-21.
40. Ballesteros AL, Miro O, Lopez S et al. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both. Antivir. Ther. 2004; 9: 969-977.
41. Vispo E, Barreiro P, Pineda JA et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir. Ther. 2008; 13: 429-437.
42. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-1713.
43. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin. Infect. Dis. 2009; 48: 313-320.
44. Housset C, Pol S, Carnot F et al. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992; 15: 578-583.
45. Puoti M, Rossi S, Forleo MA et al. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J. Hepatol. 1998; 29: 45-52.
46. Arribas JR, Gonzalez-Garcia JJ, Lorenzo A et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005; 19: 1361-1365.
47. Mathurin P, Thibault V, Kadidja K et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J. Viral Hepatol. 2000; 7: 15-22.
48. Raimondo G, Brunetto MR, Pontisso P et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43: 100-107.
49. Puoti M, Bruno R, Soriano V et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 2285-2293.
50. Soriano V, Barreiro P, Martin-Carbonero L et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J. Infect. Dis. 2007; 195: 1181-1183.
51. Chakvetadze C, Bani-Sadr F, Le Pendeven C et al. Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies. AIDS 2007; 21: 393-394.
52. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin. Liver Dis. 2006; 26: 273-284.
53. Barnes PF, Bloch AB, Davidson PT et al. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 1991; 324: 1644-1650.
54. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect. Dis. 2004; 4: 557-565.
55. Centres for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 2009; 58: 1-207.
56. Huber F, Nacher M, Aznar C et al. AIDS-related Histoplasma capsulatum var. capsulatum infection: 25 years experience of French Guiana. AIDS 2008; 22: 1047-1053.
57. Ustianowski AP, Sieu TP, Day JN. Penicillium marneffei infection in HIV. Curr. Opin. Infect. Dis. 2008; 21: 31-36.
58. Rabaud C, May T, Amiel C et al. Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey. Medicine (Baltimore) 1994; 73: 306-314.
59. Keaveny AP, Karasik MS. Hepatobiliary and pancreatic infections in AIDS: Part one. AIDS Patient Care STDS 1998; 12: 347-357.
60. Guiguet M, Boue F, Cadranel J et al. Effect of immunodefi-ciency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009; 10: 1152-1159.
61. Monforte A, Abrams D, Pradier C et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 2143-2153.
62. Brau N, Fox RK, Xiao P et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J. Hepatol. 2007; 47: 527-537.
63. Huang JS, Pan HB, Chou CP et al. Optimizing scanning phases in detecting small(< 2 cm) hepatocellular carcinoma: whole-liver dynamic study with multidetector row CT. J. Comput. Assist. Tomogr. 2008; 32: 341-346.
64. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf. 2005; 28: 53-66.
65. Soriano V, Puoti M, Garcia-Gasco P et al. Antiretroviral drugs and liver injury. AIDS 2008; 22: 1-13.
66. AIDS Clinical Trials Group. Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases, 1996.
67. Lankisch TO, Moebius U, Wehmeier M et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology. 2006; 44: 1324-1332.
68. El-Sadr WM, Lundgren JD, Neaton JD et al. CD4 + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 2006; 355: 2283-2296.
69. Reisler RB, Han C, Burman WJ et al. Grade 4 events are as important as AIDS events in the era of HAART. J. Acquir. Immune. Defic. Syndr. 2003; 34: 379-386.
70. Kaplowitz N. Drug hepatotoxicity. Sem. Liver Dis. 1990; 10: 234-235.
71. Torti C, Lapadula G, Puoti M et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER cohort. J. Acquir. Immune. Defic. Syndr. 2006; 41: 180-185.
72. Nunez M, Lana R, Mendoza JL et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 2001; 27: 426-431.
73. Bonfanti P, Landonio S, Ricci E et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 2001; 27: 316-318.
74. Aranzabal L, Casado JL, Moya J et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin. Infect. Dis. 2005; 40: 588-593.
75. Jain MK. Drug-induced liver injury associated with HIV medications. Clin. Liver Dis. 2007; 11: 615-639, vii-viii.
76. Kaplowitz N. Drug-induced liver injury. Clin. Infect. Dis. 2004; 38(Suppl. 2): S44-48.
77. Laguno M, Milinkovic A, de Lazzari E et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir. Ther. 2005; 10: 423-429.
78. Sulkowski MS, Mehta SH, Torbenson M et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585-592.
79. Piroth L. Liver steatosis in HIV-infected patients. AIDS Rev. 2005; 7: 197-209.
80. McGovern BH, Ditelberg JS, Taylor LE et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin. Infect. Dis. 2006; 43: 365-372.
81. Maida I, Babudieri S, Selva C et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. AIDS Res. Hum. Retroviruses 2006; 22: 139-143.
82. Maida I, Garcia-Gasco P, Sotgiu G et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir. Ther. 2008; 13: 103-107.
83. Ingiliz P, Valantin MA, Duvivier C et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49: 436-442.
84. Mallet V, Blanchard P, Verkarre V et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21: 187-192.